ArticleScientific reports2025
Synergistic anticancer effects of Chrysin and trastuzumab in HER2-Positive breast cancer cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnostic performance of multimodal ultrasonography for molecular subtyping of breast cancer: a retrospective study.Gland surgery · 2026Article
- Anticancer Activity and Cell Mechanism of a Novel Flavonoid Derivative fromCancer management and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HER2-positive breast cancer is an aggressive subtype with limited therapeutic options. Trastuzumab, a monoclonal antibody targeting the HER2 receptor, has improved clinical outcomes; however, its efficacy remains a critical challenge in the HER2-positive model. This study investigated the potential of chrysin, a naturally occurring flavonoid, to enhance the efficacy of trastuzumab in HER2-positive SKBR3 and BT-474 breast cancer cells. The effects of chrysin and trastuzumab, alone or in combination, were evaluated in SKBR3 and BT-474 cells. Cell viability was evaluated using an MTT assay, and the combination index (CI) value was determined using Compusyn software. Apoptosis and HER2 expression were analyzed by flow cytometry. The morphological characteristics of apoptosis were evaluated using the DAPI-TUNEL staining. Protein expression of STAT3 and PDL-1 was detected by western blotting. Real-time PCR was employed to quantify the angiogenesis-related genes. Chrysin enhanced the anticancer effects of trastuzumab, achieving an optimal combination index (CI) of 0.39 in SKBR3 cells and a similarly strong synergistic profile in BT-474 cells (CI = 0.54). Chrysin synergistically enhanced trastuzumab-induced apoptosis in both cell lines (p < 0.01 and p < 0.001). Trastuzumab significantly reduced HER2 expression on SKBR3 and BT-474 cells (p < 0.001) and, surprisingly, chrysin also reduced HER2 expression in a significant manner (p < 0.001). Combination therapy further intensified this effect in SKBR3 and BT-474 cells (p < 0.001 and p < 0.01, respectively). Additionally, the combination therapy significantly decreased p-STAT3 and PD-L1 protein levels in SKBR3 and reduced mRNA levels of Tie2 and VEGFR2 in both cell lines. Chrysin synergistically enhances the efficacy of trastuzumab in HER2-positive SKBR3 and BT-474 breast cancer cells. These findings warrant further investigation in immune-competent and in vivo models to assess clinical applicability and underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.